Europe Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) - Industry Trends and Forecast to 2030.
Europe Lung Cancer Diagnostics Market Analysis and Insights
The Europe lung cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. Increasing lung cancer diagnosis and development research is further projected to boost market growth. However, difficulties in lung cancer screening techniques might hamper the growth of the Europe lung cancer diagnostics market in the forecast period.
Increasing healthcare expenditure on cancer diagnosis and treatment is expected to give opportunities to the market to enhance the treatment. However, the high cost of testing and strict regulations and standards for the approval and commercialization of cancer diagnostic products may challenge market growth.
The Europe lung cancer diagnostics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the Europe lung cancer diagnostics market will grow at a CAGR of 13.3% during the forecast period of 2023 to 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2020 - 2015)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales)
|
|
Countries Covered
|
Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others
|
Market Definition
Cancer begins in the lungs and most often occurs in people who smoke. Two major types of lung cancer are non-small cell lung cancer and small cell lung cancer. Causes of lung cancer include smoking, second-hand smoke, exposure to certain toxins, and family history.
Symptoms include a cough (often with blood), chest pain, wheezing, and weight loss. These symptoms often don't appear until the cancer is advanced. Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy.
Europe Lung Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
- Increasing early diagnosis of lungs cancer
Machine learning could revolutionize early cancer diagnosis, which trains computers to see patterns in complex data. Tools include assessments of common health data, medical imaging, biopsy samples, and blood tests to help in early diagnosis and risk stratification. In many tumor types, the likelihood of undergoing successful therapy increases with an early cancer diagnosis. One important strategy is to assess patients at risk who do not exhibit symptoms and respond quickly and appropriately to those who do.
The likelihood of successfully treating cancer is considerably increased by early identification. The two elements of early cancer detection are screening and early diagnosis (or downstaging). While screening consists of evaluating healthy individuals to find those who have cancer before any symptoms occur, early diagnosis focuses on identifying symptomatic patients as early as feasible.
- Detection of early-stage cancers often limited by high false positives and poor sensitivity
The creation of non-invasive tests that can quickly and reliably identify whether and where in the body a person has early-stage cancer is one of the most promising areas of cancer prevention research. And not just one cancer but a variety of cancers. On this front, significant advancements have been made in recent years. Several multi-cancer early detection (MCED) tests are currently under development, and they are designed to screen for multiple cancer types in otherwise healthy individuals simultaneously. However, detecting early-stage cancer is a challenge as it comes with many barriers, such as high false positives or poor sensitivity. Many cases of poor diagnostics sensitivity lead to a patient's life at risk. The high false positives are also one of the causes of cancer advancing to late stages or advanced stages.
Thus, the detection of early-stage cancers is often limited by high false positives, and sometimes poor sensitivity may act as a major restraining factor for the growth of the Europe lung cancer diagnostics market.
- Rise in healthcare expenditure for cancer diagnosis and treatment
Across the globe, research and development activities are escalating owing to the public health expenditure with economic performances. Whereas the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of research and development opportunities. It is anticipated to increase the demand for lung cancer diagnostics. Increasing the healthcare expenditure for cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and sources. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is an opportunity to grow the market's demand.
- Lack of skilled and certified professionals
The requirement of skilled and certified professionals is a big restraint for cancer diagnostics. The demand for cancer diagnostic is increased due to increasing cases of cancer disease in the globe, but the fewer number of skilled professionals present in the diagnostic center is hampering the growth of the market.
The instruments, methods, and procedures of cancer diagnosis have been advanced, but there are certain gaps in standardization, equalization, and knowledge. Technicians face technical training gaps related to problems and adapt advanced methods safely to perform procedures efficiently. In cancer diagnostics, skilled professionals are highly needed for method development, validation, operation, and troubleshooting activities.
A cancer diagnosis is a dynamic component in today's complex time, providing patients with essential information for diagnosing, preventing, treating, and managing their cancer disease. The requirement for trained staff is a big issue for the Europe lung cancer diagnostics market. Due to the lack of skilled and certified professionals, end users cannot install advanced products for a cancer diagnosis; this may challenge the growth of the Europe lung cancer diagnostics market.
Post-COVID-19 Impact on Europe Lung Cancer Diagnostics Market
The high burden of COVID-19 on healthcare systems around the world has raised concerns among medical oncologists about the impact of COVID-19 on lung cancer diagnosis and treatment. We investigated the impact of COVID-19 on lung cancer diagnosis and treatment before and after the COVID-19 era in this retrospective cohort study. During the pandemic, new lung cancer diagnoses decreased by 34.7% with slightly more advanced stages of the disease, and there was a significant increase in radiosurgery as the first definitive treatment and a decrease in systemic treatment and surgery compared to the pre-COVID-19 era. Compared to pre-COVID-19 times, there was no significant delay in starting chemotherapy and radiation treatment during the pandemic.
During the pandemic, however, we observed a delay in lung cancer surgery. COVID-19 appears to have significantly impacted lung cancer patients' diagnoses and treatment patterns at our lung cancer center. Many oncologists are concerned that the number of newly diagnosed lung cancer patients will rise in the coming year. This research is still ongoing, and more information will be gathered and analyzed to understand better the overall impact of the COVID-19 pandemic on our lung cancer patient population.
Recent Developments
- In October 2022, Quest Diagnostics announced a new chapter of the partnership with Decode Health. This partnership has aided the business in decreasing the time and expense involved in creating fresh diagnostic tests and finding new medication targets for various cancers and increased the company's Europe presence
- In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System, a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases
Europe Lung Cancer Diagnostics Market Scope
The Europe lung cancer diagnostics market is categorized into five notable segments based on product type, test type, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & Accessories
On the basis of product type, the Europe lung cancer diagnostics market is segmented into instruments, consumables & accessories.
Test Type
- Biomarkers Tests
- Imaging Test
- Biopsy
- Blood Test
- Others
On the basis of test type, the Europe lung cancer diagnostics market is segmented into imaging test, biomarkers test, biopsy, blood test, and others.
Cancer Type
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
On the basis of cancer type, the Europe lung cancer diagnostics market is segmented into non-small cell lung cancer and small cell lung cancer.
End User
- Hospital
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
On the basis of end user, the Europe lung cancer diagnostics market is segmented into hospital, associated labs, independent diagnostics laboratories, diagnostic imaging centers, cancer research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the Europe lung cancer diagnostics market is segmented into direct tender and retail sales.
Europe Lung Cancer Diagnostics Market Regional Analysis/Insights
The Europe lung cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, end user, and distribution channel, as referenced above.
Some countries covered in the Europe lung cancer diagnostics report Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe.
Germany is expected to dominate the Europe lung cancer diagnostics market due to increasing technology and reliability of healthcare services, which also deliver infotainment services.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Lung Cancer Diagnostics Market Share Analysis
The Europe lung cancer diagnostics market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Europe lung cancer diagnostics market.
Some players in the Europe lung cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others.
SKU-